New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)
The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the efficacy and safety of new insulin glargine 300 units/mL (Gla-300) with glargine 100 units/mL (Gla-100) in people with type 2 diabetes using basal insulin (≥42 units/day) plus oral antihyperglycemic drugs (OADs). RESEARCH DESIGN AND METHODS: EDITION 2 was a multicenter, open-label, two-arm study. Adults receiving basal insulin plus OADs were randomized to Gla-300 or Gla-100 once daily for 6 months. The primary end point was change in HbA1c. The main secondary end point was percentage of participants with one or more nocturnal confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycemic events from week 9 to month 6. RESULTS: Randomized participants (n = 811) had a mean (SD) HbA1c of 8.24% (0.82) and BMI of 34.8 kg/m2 (6.4). Glycemic control improved similarly with both basal insulins; least squares mean (SD) reduction from baseline was −0.57% (0.09) for Gla-300 and −0.56% (0.09) for Gla-100 (mean difference −0.01% [95% CI −0.14 to 0.12]), with 10% higher dose of Gla-300. Less nocturnal confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycemia was observed with Gla-300 from week 9 to month 6 (relative risk 0.77 [95% CI 0.61–0.99]; P = 0.038) and during the first 8 weeks. Fewer nocturnal and any time (24 h) hypoglycemic events were reported during the entire 6-month period. Weight gain was lower with Gla-300 than with Gla-100 (P = 0.015). No between-treatment differences in safety parameters were identified. CONCLUSIONS: Gla-300 was as effective as Gla-100 and associated with a lower risk of hypoglycemia during the night and at any time of the day.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but about 7% to 15% of insulin-treated persons with T2D experience at least 1 episode of hypoglycemia per year,1109 and 1% to 2% have severe hypoglycemia.1106,1108”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1106]
In the citing paper
“Hypoglycemia and weight gain are the most common adverse effects of insulin therapy.1106,1107”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1106]
In the citing paper
“U-300 glargine has a longer duration of action than U-100 glargine but modestly lower efficacy per unit administered (179-181).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [181]
Citations
Cites
Levey, A. S., Coresh, J., Balk, E., Kausz, A. T., Levin, A., Steffes, M. W., Hogg, R. J., Perrone, R. D., Lau, J., & Eknoyan, G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00013 · Cited by 4,615 · cited 1×
“5 rapidly progressing diabetic retinopathy (which may likely require laser/surgical treatment during the study), end-stage renal disease (defined as those participants requiring dialysis or transplantation (12)), or clinically significant cardiac, hepatic, or other systemic disease.”
BackgroundBasal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479 · cited 3×
“3 Insulin glargine 100 U/mL (Gla-100) is a once-daily, long-acting basal insulin analog, which induces less hypoglycemia than neutral protamine Hagedorn (NPH) insulin (1).”
BackgroundDefining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655 · cited 1×
“adherence to the treatment regimen (7,8).”
Psychological Insulin Resistance in Patients With Type 2 Diabetes
Polonsky, W. H., Fisher, L., Guzman, S., Villa-Caballero, L., & Edelman, S. V. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2543 · Cited by 551
Becker, R. H. A., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., & Heise, T. (2015) · Diabetes Care · doi:10.2337/dc14-0006 · Cited by 407 · cited 2×
“After subcutaneous injection, Gla-300 has been shown to have smoother, more stable, and prolonged pharmacokinetic and pharmacodynamic profiles than Gla-100, resulting from an extended release of glargine from the subcutaneous depot (9).”
BackgroundRiddle, M. C., Bolli, G. B., Ziemen, M., Muehlen-Bartmer, I., Bizet, F., & Home, P. D. (2014) · Diabetes Care · doi:10.2337/dc14-0991 · Cited by 354
Self-citationInsulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators (2012) · Diabetes Care · doi:10.2337/dc12-1205 · Cited by 336
Bretzel, R. G., Nuber, U., Landgraf, W., Owens, D. R., Bradley, C., & Linn, T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60485-7 · Cited by 305 · cited 1×
“Its efficacy in achieving and maintaining target glycemic control and safety profile in terms of cardiovascular risk and cancer is well documented (1-6).”
Background
Cited by
Items 101–200 of 284
the RESTORE-1 Study Group, Laviola, L., Porcellati, F., Bruttomesso, D., Larosa, M., Rossi, M. C., & Nicolucci, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00982-z · Cited by 16
Perez, A., Carrasco-Sánchez, F. J., González, C., Seguí-Ripoll, J. M., Trescolí, C., Ena, J., Borrell, M., & Gomez Huelgas, R. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001518 · Cited by 16
Understanding concentrated insulins: a systematic review of randomized controlled trials
Ovalle, F., Segal, A. R., Anderson, J. E., Cohen, M. R., Morwick, T. M., & Jackson, J. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1409426 · Cited by 16
White, J. R. (2016) · Clinical Diabetes · doi:10.2337/diaclin.34.2.86 · Cited by 16
Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?
Bonadonna, R. C., Renard, É., CHENG, A. Y. Y., Fritsche, A., Cali, A. M. G., Melas‐Melt, L., & Umpierrez, G. E. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.03.041 · Cited by 16
Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes
Chatterjee, S., Khunti, K., & Davies, M. J. (2019) · Drugs · doi:10.1007/s40265-018-1048-6 · Cited by 15
Oster, G., Sullivan, S. D., Dalal, M. R., Kazemi, M. R., Rojeski, M., Wysham, C., Sung, J., Johnstone, B. M., Cali, A. M. G., Wei, L. J., et al. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1241663 · Cited by 15
Frias, P. F., & Frías, J. P. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0926-8 · Cited by 15
Ultra-long-acting insulins: A review of efficacy, safety, and implications for practice
Davis, C. S., Fleming, J. W., Malinowski, S. S., Brown, M. A., & Fleming, L. W. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000076 · Cited by 17
Meneghini, L., Sullivan, S. D., Oster, G., Busch, R. S., Cali, A. M. G., Dauchy, A., Gill, J., & Bailey, T. S. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14152 · Cited by 15
Monnier, L., Owens, D. R., & Bolli, G. B. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.11.005 · Cited by 14
Lajara, R., Cengiz, E., & Tanenberg, R. J. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1298522 · Cited by 15
The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin
Shaefer, C. F., & Anderson, J. E. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2016.1103640 · Cited by 15
Kişioğlu, S. V., Demır, A. S., Tüfekçi, D., Günay, Y., Coşkun, H., Üçüncü, Ö., Nuhoğlu, İ., Koçak, M., Karakullukçu, S., & Ersöz, H. Ö. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14377 · Cited by 14
Pohlmeier, H., Berard, L., Brulle-Wohlhueter, C., Wu, J., Dahmen, R., NOWOTNY, I. K., & Klonoff, D. C. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816668877 · Cited by 13
Hurren, K. M., & O’Neill, J. L. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1245722 · Cited by 13
New Injectable Agents for the Treatment of Type 2 Diabetes Part 1 – Injectable Insulins
George, C. M., Byun, A., & Howard-Thompson, A. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.01.049 · Cited by 13
Wieringa, T. H., de Wit, M., Twisk, J. W. R., & Snoek, F. J. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000548 · Cited by 13
Sleeman, A., ODOM, J. M., & Schellinger, M. M. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028019897897 · Cited by 14
Jain, S. M., Seshadri, K., Unnikrishnan, A. G., Chawla, M. S., Kalra, P., Vipin, V. P., Ravishankar, E., Chordia, J., Das, S., Wasir, J. S., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00770-9 · Cited by 13
Navigating Insulin Options for Diabetes Management
Rafi, E., Tranchito, L. J., & Hatipoğlu, B. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae790 · Cited by 12
Segal, A. R., Vootla, T., & Beaser, R. S. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.009 · Cited by 14
Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus
Frier, B. M., Ratzki‐Leewing, A. A., & Harris, S. B. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13732 · Cited by 12
Joshi, S., Singh, G., Marwah, A., Mittra, S., Suvarna, V. R., & Athalye, S. N. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15007 · Cited by 12
Olofsson, S., Norrlid, H., & Persson, U. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1187152 · Cited by 12
Long-Acting Basal Insulins: A Review of the More Recently Approved Agents
Aragon, K. G., Elmaoued, A. A., Pham, N.-Y. T., Conklin, J. R., & Ray, G. M. (2019) · Cardiology in Review · doi:10.1097/crd.0000000000000266 · Cited by 12
“015).(18) A 6-month extension study demonstrated that the initial reduction in A1C of both groups was sustained at 12 months with a LSMD in A1C change from baseline to month 12 of –0.”
BackgroundResultU300 Insulin Glargine: A Novel Basal Insulin for Type 1 and Type 2 Diabetes
Rosselli, J. L., Archer, S. N., Lindley, N. K., & Butler, L. M. (2015) · Journal of Pharmacy Technology · doi:10.1177/8755122515584193 · Cited by 12
Klonoff, D. C., Nayberg, I., Thonius, M., See, F., Tawab, M. A., Erbstein, F., & Haak, T. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815601441 · Cited by 13
Insulin glargine 300U/ml in the management of diabetes: clinical utility and patient perspectives
de Galan, B. E. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s92123 · Cited by 12
“Two studies reported that use of glargine-300 caused 0.5 and 1.0 kg lower weight gain than use of glargine-100, respectively, 23,27 but this weight benefit was not achieved in two other studies.”
InfluentialRosenstock, J., BAJAJ, H. S., Lingvay, I., & Heller, S. R. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003930 · Cited by 12
Wiesli, P., & Schories, M. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0518-x · Cited by 13
Gourdy, P., Bahloul, A., Boultif, Z., Gouet, D., & Guerci, B. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00734-8 · Cited by 11
“This interventional phase IV study could not be compared to the phase III EDITION 2 study [11] or the real-world evidence DELIVER 2 study [12] as these studies were different by design.”
MethodMeneghini, L., Blonde, L., Gill, J., Dauchy, A., Bacevicius, A., Strong, J. L., & Bailey, T. S. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14116 · Cited by 11
rDNA insulin glargine U300 – a critical appraisal
Wang, F., Zassman, S., & Goldberg, P. A. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s87873 · Cited by 14
“The Phase III EDITION trials were adequately powered to demonstrate a noninferiority margin of 0.4% for the comparison to Gla-100.”
InfluentialPearson, S. M., & Trujillo, J. M. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818760962 · Cited by 12
Kalra, S. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_300_17 · Cited by 11
Switching basal insulins in type 2 diabetes: practical recommendations for health care providers
Anderson, S. L., Trujillo, J. M., Anderson, J. E., & Tanenberg, R. J. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1419048 · Cited by 11
“Patients who switched from NPH insulin or Gla-100 to Gla-300 in the EDITION trials showed similar glycemic control with less risk of overall and nocturnal hypoglycemia compared with those who switched to Gla-100 [16,17].”
BackgroundColin, I. M., Alexandre, K., Bruhwyler, J., Scheen, A. J., & Verhaegen, A. A. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00866-2 · Cited by 10
Current usage of long-acting insulin analogs in patients with type 2 diabetes mellitus
Aktaş, G., & Duman, T. T. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2320631 · Cited by 10
“However, less nocturnal hypoglycemia was observed in the clinical study with patients with type 2 diabetes [24–28].”
BackgroundValencia, W. M., Florez, H. J., & Palacio, A. M. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00706-4 · Cited by 10
“The analyses from the EDITION studies demonstrated a significantly lower risk of hypoglycemia with Gla-300, with fewer participants reporting nocturnal or severe hypoglycemia episodes, in both insulin-naïve [48] and insulin-experienced [49] patients.”
MethodShingaki, T., Taki, K., Koyanagi, M., Nagaoka, S., Yoshizawa, K., Oki, N., Yoshikawa, A., & Imaoka, T. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1754182 · Cited by 10
Vargas‐Uricoechea, H., & Pablo, F. J. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.05.001 · Cited by 11
Bohn, B., Bramlage, P., Wagner, C., Kaltheuner, M., Welp, R., Sziegoleit, S., Zimmermann, A., Reuter, H. M., Hummel, M., Gloyer, J., et al. (2017) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-017-0589-8 · Cited by 9
Hompesch, M., Patel, D. K., LaSalle, J. R., & Bolli, G. B. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1568136 · Cited by 10
Wright, E. E., Malone, D. C., Trujillo, J. M., Gill, J., Huse, S., Li, X., Zhou, F. L., Preblick, R., & Reid, T. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.21436 · Cited by 9
Novel Concentrated Insulin Delivery Devices: Developments for Safe and Simple Dose Conversions
Johnson, J. L., Downes, J. M., Obi, C. K., & Asante, N. B. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816680830 · Cited by 9
Nakanishi, S., Iwamoto, M., Kamei, S., Hirukawa, H., Shimoda, M., Tatsumi, F., Kohara, K., Obata, A., Kimura, T., Kinoshita, T., et al. (2018) · Internal Medicine · doi:10.2169/internalmedicine.9334-17 · Cited by 9
Escalada, J., Bonnet, F., Wu, J., Bonnemaire, M., Gupta, S., Cambron‐Mellott, M. J., Nicholls, C. J., & Müller‐Wieland, D. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01436-5 · Cited by 9
Brunton, S., Kruger, D. F., & Funnell, M. M. (2016) · Clinical Diabetes · doi:10.2337/diaclin.34.1.34 · Cited by 8
Hirose, T., Chen, C., Ahn, K. J., & Kiljanski, J. I. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0613-7 · Cited by 8
Concentrated Insulins: A Review and Recommendations.
Gonzalvo, J. D., Patel, D. K., & Olin, J. L. (2017) · Europe PMC (PubMed Central) · Cited by 8
Vargas‐Uricoechea, H., Núñez, J. L. B., Guzmán, J. R., Silva‐Gomez, L., Beltran, S., & Sañudo‐Maury, M. E. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14868 · Cited by 8
Cummings, M. H., Cao, D., Hadjiyianni, I., Ilag, L. L., & Tan, M. H. (2018) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-018-0059-2 · Cited by 8
Seufert, J., Wiesli, P., Fritsche, A., Anderten, H., Pegelow, K., Pscherer, S., & Pfohl, M. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14549 · Cited by 8
Bonadonna, R. C., Yale, J., Brulle‐Wohlhueter, C., Boëlle‐Le Corfec, E., Choudhary, P., & Bailey, T. S. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13578 · Cited by 7
A primer on concentrated insulins: what an internist should know
Barnosky, A., Shah, L., Meah, F. A., Emanuele, N., Emanuele, M. A., & Mazhari, A. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1159909 · Cited by 8
Zhou, F. L., Nicholls, C. J., Xie, L., Wang, Y., Vaidya, N., & Meneghini, L. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.73 · Cited by 7
van Mark, G., Lanzinger, S., Sziegoleit, S., Putz, F. J., Durmaz, M., Borscheller, M., Danne, T., Seufert, J., Holl, R. W., & Bramlage, P. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00983-w · Cited by 7
Prázný, M., Flekač, M., Jelínek, P., & Mašková, J. (2020) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2020.103010 · Cited by 7
Insulin U100, 200, 300 or 500?
Dashora, U. K., & Castro, E. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.056 · Cited by 10
Goldman, J. D., Gill, J., Horn, T., Reid, T., Strong, J. L., & Polonsky, W. H. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0501-6 · Cited by 7
Kamenov, Z. A., Pehlivanova, V., Kuneva, T., Kirilov, K., Bobeva, R., Stoykova, J., & Mihalevska, S. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01022-0 · Cited by 7
Velojić-Golubović, M., Ćirić, V. M., Dimitrijevic, M., Ković, T., Mitic, M., Olujic, B., Pevac, N., Radenković, S., Radojković, D., Vukadinovic, S., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01074-2 · Cited by 7
Basal insulin analogues in people with diabetes and chronic kidney disease
Jiménez, D. L., Miramontes‐González, J. P., Márquez‐López, L., Astudillo‐Martín, F., Beltrán, L. M., Obregón, F. M., & Martín, J. E. (2021) · Diabetic Medicine · doi:10.1111/dme.14679 · Cited by 7
Roussel, R., d'Emden, M. C., Fisher, M., Ampudia‐Blasco, F. J., Stella, P., Bizet, F., Cali, A. M. G., & Wysham, C. H. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13071 · Cited by 6
Monnier, L. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30031-7 · Cited by 6
Twigg, S. M., Escalada, J., Stella, P., Merino‐Trigo, A., Lavalle-Gonzalez, F. J., Cariou, B., & Meneghini, L. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0498-x · Cited by 6
Malik, R. A., Elhadd, T. A., Alattar, A., Shaikh, A. A., Alrandi, M., Arora, R., Alsifri, S. N., Akil, Y. A., Magdy, A., Naqvi, M., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01225-z · Cited by 6
Fadini, G. P., Buzzetti, R., Nicolucci, A., Larosa, M., Rossi, M. C., Cucinotta, D., On behalf of the RESTORE-2 Study Group, Gabellieri, E., Alberto, M., Pagotto, U., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01925-9 · Cited by 7
Recent advances in management of type 1 diabetes
Pyrlis, F., Brown, F., & Ekinci, E. I. (2019) · Australian Journal of General Practice · doi:10.31128/ajgp-12-18-4775 · Cited by 6
Napoli, R., Fanelli, F., Gazzi, L., Larosa, M., Bitonti, R., & Furneri, G. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.07.005 · Cited by 6
Bae, J. H., Ahn, C. H., Yang, Y., Moon, S. J., Kwak, S. H., Jung, H. S., Park, K. S., & Cho, Y. M. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0274 · Cited by 7
“In the EDITION 2 trial, the participants were mainly Caucasians, with a body mass index (BMI) of 34.8±6.4 kg /m 2 at baseline [5].”
InfluentialPréparations insuliniques au cours de la dernière décennie.
Monnier, L., & Colette, C. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30034-8 · Cited by 5
Tabák, Á. G., Kempler, P., Guja, C., Eldor, R., Haluzík, M., Klupa, T., Παπάνας, Ν., Stoian, A. P., & Mankovsky, B. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01556-z · Cited by 5
“Furthermore, compared to first-generation analogues (glargine [Gla]-100/insulin detemir [IDet]), second-generation analogues (Gla-300/insulin degludec [IDeg]-100) with a prolonged duration of action and greater flexibility have demonstrated comparable glycaemic control with enhanced safety [38–40].”
Bolli, G. B., Wysham, C., Fisher, M., Chevalier, S., Cali, A. M. G., Leroy, B., & Riddle, M. C. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13515 · Cited by 5
“In theory, the use of sulphonylureas and/or glinides in the EDITION JP 2 trial might have confounded the results of the present pooled analysis, as sulphonylureas increase the risk of hypoglycaemia(11) and were not allowed in the EDITION 2 and 3 trials.(6,8) However, such confounding seems unlikely because a similar p…”
MethodResultSelf-citationMauricio, D., Westerbacka, J., Nicholls, C. J., Wu, J., Gupta, R., & Eliasson, B. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14264 · Cited by 5
Échec des antidiabétiques oraux à doses maximales tolérées : Quels traitements injectables?
Monnier, L., & Colette, C. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30030-x · Cited by 6
The role of Toujeo®, insulin glargine U‐300, in the treatment of diabetes mellitus
Brown, M. A., Davis, C. S., Fleming, L. W., & Fleming, J. W. (2016) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12357 · Cited by 5
“Even with the higher insulin dosage, there was significantly less weight gain in the Gla-300 group (0.08 kg) as compared to the Gla-100 group (0.66 kg; p = 0.015; Yki-Jarvinen et al., 2014).”
BackgroundMethodResultInfluentialRiddle, M. C., Bolli, G. B., Avogaro, A., Álvarez, M. G., Merino‐Trigo, A., Corfec, E. B., & Home, P. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.12.001 · Cited by 5
Self-citationJi, L., Bi, Y., Ye, S., Huang, Y., Zhang, X., Shang, S., Cui, N., Yin, H., & Zhang, M. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108848 · Cited by 5
Ragonese, M., Larosa, M., Angotti, S., Annese, S., Cruciani, L., Dainelli, M., Lucisano, G., Prosperini, G., Sacco, M., Salomone, E., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00902-1 · Cited by 5
Monnier, L., & Halimi, S. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30031-1 · Cited by 4
Sullivan, S. D., Freemantle, N., Gupta, R. A., Wu, J., Nicholls, C. J., Westerbacka, J., & Bailey, T. S. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.306 · Cited by 4
Okajima, F., Nakamura, Y., Yamaguchi, Y., Shuto, Y., Kato, K., Sugihara, H., & Emoto, N. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0419-z · Cited by 4
Riddle, M. C., Peters, A. L., & Funnell, M. M. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1177969 · Cited by 4
Self-citationAdvances in Basal Insulin Therapy
Goldman, J. D., & White, J. R. (2016) · Journal of Pharmacy Technology · doi:10.1177/8755122516667128 · Cited by 4
Chang, C., & Chuang, L. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12776 · Cited by 4
Clinical Challenges With Concentrated Insulins: Setting the Record Straight
Brusko, C., Taylor, A. D., Jackson, J. A., & Bunck, M. C. M. (2017) · Diabetes Spectrum · doi:10.2337/ds17-0008 · Cited by 4
“When switching to concentrated insulins in insulinexperienced patients, which may be the more common clinical scenario, the starting dose for IGlar300 and IDeg200 should be the same as the previous total daily basal insulin dose; exceptions include a 20% reduction for patients on twice-daily NPH insulin (when switchin…”
BackgroundTerauchi, Y., Riddle, M. C., Hirose, T., Koyama, M., Cheng, X., Takahashi, Y., & Bolli, G. B. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13414 · Cited by 4
Self-citationIto, H., Tsugami, E., Ando, S., Araki, R., Matsumoto, S., Uemura, K., Nishio, S., Antoku, S., Yamasaki, T., Mori, T., et al. (2018) · Journal of Drug Assessment · doi:10.1080/21556660.2018.1513846 · Cited by 4
Si l'ère des insulines semi-synthétiques et biosynthétiques nous était contée
Monnier, L., Colette, C., & Owens, D. R. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(21)00178-4 · Cited by 5
Khan, N. E., Shaikh, A. A., Hassoun, A. A. K., Hassan, A. M., Salah, M. M., Abdella, N. A. A., Safarini, S., Dahi, W. A. A., & Akil, Y. A. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01537-2 · Cited by 4
Nocturnal Glycemic Control with New Insulin Glargine 300 U/mL
Yu, N. C. (2019) · Advances in Medicine · doi:10.1155/2019/8587265 · Cited by 4
Liu, S., Xu, J., Yuan, Z., Mei, Z., Shi, S., Yin, J., & Deng, Y. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331489 · Cited by 3
“Previous research has highlighted several safety concerns associated with IG treatment, such as hypoglycemia and its impact on weight gain [10–12].”
Strong, J. L., Kruger, D. F., & Novak, L. M. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1288614 · Cited by 3
Higher concentration insulins: an overview of clinical considerations
Reid, T., Schafer, F., & Brusko, C. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1325311 · Cited by 3
“EDITION 1 [40] and 2 [41] and ~15% higher in EDITION 3 [39].”
BackgroundMethodMonnier, L., Halimi, S., & Colette, C. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30007-5 · Cited by 5
Shestakova, M. V., & Galstyan, G. R. (2017) · Problems of Endocrinology · doi:10.14341/probl2017634257-268 · Cited by 3
Yale, J., Pettus, J., Brito-Sanfiel, M. Á., Lavalle-Gonzalez, F. J., Merino‐Trigo, A., Stella, P., Chevalier, S., & Buzzetti, R. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190579 · Cited by 3
Frechtel, G. D., Forti, L., Faingold, C., Manghi, F. P., Orio, S. I., Issa, C. M., Guaita, M. S., Vivas, N., & luca, J. D. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.164 · Cited by 3
Metadata
- Authors
- Yki-Järvinen, H., Bergenstal, R., Ziemen, M., Wardecki, M., Muehlen-Bartmer, I., Boelle, E., & Riddle, M. C.
- Affiliations
- Department of Medicine, University of Helsinki, and Minerva Foundation Institute for Medical Research, Helsinki, Finland
- Park Nicollet Health Services (US)
- Sanofi (Germany) (DE)
- Sanofi, Warsaw, Poland
- Sanofi, Paris, France
- Oregon Health & Science University (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-11-08
- Volume
- 37
- Issue
- 12
- Pages
- 3235-3243
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4230570152
- Cited by
- 274
- References
- 17
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 18 · 2023: 7 · 2022: 19 · 2021: 15 · 2020: 29 · 2019: 29 · 2018: 47 · 2017: 33 · 2016: 40 · 2015: 23 · 2014: 2
- FWCI
- 26.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin glargine, type 2 diabetes, basal insulin, oral antidiabetic drugs, glycemic control, HbA1c, hypoglycemia, nocturnal hypoglycemia, weight gain, insulin dose reduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.